Sanofi Inks Letter Of Intent With pan-Canadian Pharmaceutical Alliance For Dupixent For Four Additional Indications
Sanofi today announced the successful completion of negotiations between the pan-Canadian Pharmaceutical Alliance (pCPA) and Sanofi with a signed Letter of Intent (LOI) for Dupixent for four additional indications:
Sanofi got approval to sell a medicine called Dupixent for four new uses in Canada. When a company can sell one medicine for more uses, it means more customers and potentially more money.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.